July 4, 2009
| Bio-IT World > Sequence Gazing
Sequence Gazing


May 15, 2007 | The prodigious output from next-generation sequencing platforms offers exciting opportunities for sequence software specialists too. Tom Schwei, general manager of Madison, WI-based DNAStar, says that for almost 20 years, his company’s Lasergene software has “done a nice job of the ‘blocking and tackling’ of sequencing analysis” — sequence assembly, analysis, gene identification, and visualization. “We’ve been there, we’re still there, and we’re going to be there. It’s incredibly important to scientists using our product.”

Schwei says the most recent release of Lasergene had “a powered up assembly engine aimed at areas where next-generation sequencing is coming into play — taking Sanger data and complementing those with 454 data, and finding ways to do successful assemblies.”

While Lasergene is primarily a desktop tool useful for modestly sized genomes, DNAStar is developing a new genome assembler tool, currently in alpha testing with a couple of labs, including GATC Biotech in Germany (it recently purchased 454 and Solexa instruments.) “This could be powered up on a Linux cluster to handle larger organisms,” says Schwei. It takes better advantage of paired-end reads, using them for assembly, not just alignment. And “Because of the way the processing algorithm works, it processes several times faster than Lasergene. If you can use clusters, you will ultimately be able to do even greater than that.”

“Our philosophy is we want to be able to work with all the kinds of data out there. The closer our realationship to the manufacturers, the better. We’re not looking to replace the software they distribute... that’s not our goal. But we expect great value to end users as software that can handle 454, Solexa, Applied Bio, Helicos, and Sanger,” says Schwei.

“If one software package can take all those types of data and work well with those, that’s a tool that will be very valuable to many scientists.” -- K.D.

Return to main article.


Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

thomson reuters image
Biomarkers: An Indispensible Addition to the Drug Development Toolkit
Examining the Potential of Biomarkers
Sponsored by Thomson Reuters

Biomarkers are becoming an essential part of clinical development. In this white paper, Thomson Reuters provides insight from experts in industry and academia, and explores the role of biomarkers as evaluative tools in improving clinical research and the challenges this presents.

Discover the potential of biomarkers to:

  • Improve decision making
  • Accelerate drug development
  • Reduce development costs


BlueArc_Scientific Data
Scientific Data Lifecycle Management: Preparing for Storage in an Uncertain Future
Sponsored by BlueArc

Managing vast and overwhelming streams of gene sequencing data today requires ultra-high performance systems and processes. With continued rapid advancement and improvements in gene sequencing, expect tomorrow’s instruments to output quantities of genomic information that will dwarf current levels. Help your organization maintain data control and prepare for the future of sequencing through this informative paper that discusses:

  • The information technology challenges of gene sequencing
  • “Intelligent” methods for data management and customization
  • System survival tips... Deciding what data to keep or delete
  • New tools to keep scientists ahead of impending data torrents


SAS Managed image
Managed Innovation, Assured Compliance
Developing, executing and managing the transformation, analysis and submission of clinical research data with SAS® Drug Development
Sponsored by SAS
Get better products to market faster. Download this white paper to discover the top ten challenges facing life science executives and how to overcome them. See how SAS Drug Development transforms clinical data into true innovation.


Life Science Webcasts & Podcasts

Presented by Trade Commission of Spain

Spain Biotech: An Engine for Economic Change 

TCS podcastDiscover how Spain is focusing on biotechnology to be an engine for economic change through gradual internationalization, development and technology transfer.

Regional governments are actively investing in public and private biology research and promoting the creation of knowledge-based companies. Spain’s human capital combined with aggressive investment in biotech research and infrastructure has led to the creation of bio-clusters.

Today, there are nearly 700 Spanish companies engaged in biotechnology, with almost 50 percent growth in funding devoted to research. In fact, spending on internal R & D in biotechnology has grown 46 percent and is close to 300 million Euros.

Access the podcast 

 



More Podcasts

Job Openings

saic_logo

MANAGER, SCIENTIFIC COMPUTING & PROGRAMMING
(Bioinformatics Manager)
SAIC-Frederick, Inc has an exciting opportunity for a Manager, Scientific Computing & Programming - Core Genoytyping Facility in Gaithersburg, Maryland.  In this role, you will lead the Bioinformatics & Analysis Group.
Master’s or equivalent required.  PhD preferred. Six years experience in development of scientific programs in high-performance computing environment including five years supporting scientific research in computational chemistry, biology, or genetics, & two years supervisory experience.  View complete job posting & apply: www.saic-frederick.com. Position #146945.

For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.